Regentis Biomaterials Ltd（RGNT）財務資料

$2.060

+0.020 (+0.98%)收盤時

RGNT 同業比較

In the context of the broader market, RGNT competes directly with industry leaders such as INTS and BNGO. With a market capitalization of $14.05M, it holds a significant position in the sector. When comparing efficiency, RGNT's gross margin of N/A stands against INTS's N/A and BNGO's 52.80%. Such benchmarking helps identify whether Regentis Biomaterials Ltd is trading at a premium or discount relative to its financial performance.

Regentis Biomaterials Ltd 財務表現

Regentis Biomaterials has shown a significant turnaround in its financials, with total equity projected to turn positive at $4,744,000 by Q4 2025, compared to negative equity in previous quarters. This indicates improving financial health and potential for growth.

Financials

No data

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。